Johnson & Johnson (JNJ)
| Market Cap | 641.07B +37.9% |
| Revenue (ttm) | 99.34B +7.8% |
| Net Income | 16.10B -35.9% |
| EPS | 6.58 -36.4% |
| Shares Out | 2.41B |
| PE Ratio | 40.44 |
| Forward PE | 23.94 |
| Dividend | $5.36 (2.01%) |
| Ex-Dividend Date | Nov 24, 2026 |
| Volume | 5,777,445 |
| Open | 266.74 |
| Previous Close | 263.81 |
| Day's Range | 264.97 - 272.36 |
| 52-Week Range | 184.66 - 281.07 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 279.41 (+4.92%) |
| Earnings Date | Oct 13, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $279.41, which is an increase of 4.92% from the latest price.
News
Oric Pharmaceuticals drops after J&J presents prostate cancer drug data
Shares of drug developer Oric Pharmaceuticals (ORIC) are falling after competitor Johnson & Johnson (JNJ) presented data about its own potential drug to treat patients with prostate cancer at a…
Johnson & Johnson announces Phase 1 results for JNJ-6143 at ESMO 2026
Johnson & Johnson announced Phase 1 results for JNJ-6143, an investigational once-daily oral Regulated Induced Proximity Targeting Chimera small molecule, in patients with advanced prostate cancer who...
Johnson & Johnson announces results from Cohort 5 of Phase 1b/2 OrigAMI-4 study
Johnson & Johnson announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and durable responses with first-line subcutaneous amivantamab and hyaluronidase-lpuj plus a PD-1 i...
Johnson & Johnson announces results from Phase 3 PROTEUS substudy
Johnson & Johnson announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy, ADT, given for six months bef...
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
BEERSE, BELGIUM, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study with first-line subcutaneous RYBREVANT®▼ (amivantamab) ...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data h...
Johnson & Johnson (JNJ) Reports 69% Tumor Response Rate for Prostate Cancer Drug
Johnson & Johnson ($JNJ) has reported promising early results for its experimental prostate cancer pill, JNJ-6143, which has excited the oncology world. In a trial involving patients with advanced pro...
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumo...
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
BEERSE, BELGIUM , Oct. 24, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus h...
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free fro...
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial
Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial.
UK approves J&J's oral psoriasis pill
Britain's medicines regulator on Friday approved Johnson & Johnson's daily pill for adults and teenagers with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly and often itchy...
Johnson & Johnson reports real-world VARIPULSE Pro platform data
Johnson & Johnson announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific Heart Rhythm Society 2026 Annual Meeting in Busan, South Korea. Both studies…
Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson reports first real-world VARIPULSE Pro Platform data and 12-Month OMNYPULSE Platform outcomes for atrial fibrillation treatment.
3 of the Best Value Stocks to Own
#StockstoBuy #ValueStocks #TheMorningFilter These value stocks with wide economic moats are good long-term investments when you can buy them at a discount.
Johnson & Johnson downgraded to Hold from Buy at Erste Group
Erste Group downgraded Johnson & Johnson to Hold from Buy. On a sector-by-sector basis, the stock is trading at a high valuation, which leads the firm to believe its upside…
Johnson & Johnson announces U.S. launch of Shockwave C2 Aero Fly catheter
Johnson & Johnson announced the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter designed to treat a broad range of calcified coronary artery lesions in half the…
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
SANTA CLARA, Calif.--(BUSINESS WIRE)--Next-generation IVL catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease.
Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026
ABU DHABI, United Arab Emirates--(BUSINESS WIRE)-- #PressRelease--Johnson & Johnson will showcase digital surgery technologies and its Department of Health - Abu Dhabi collaboration at the Future Heal...
Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn's disease and expanding evidence in perianal fistula
BEERSE, BELGIUM (19 October 2026) – Johnson & Johnson today announced new data that further expands the clinical evidence supporting TREMFYA® (guselkumab) in Crohn's disease (CD) at the 2026 United Eu...
Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally
Johnson & Johnson’s ($JNJ) rally has me holding off, despite an improving business. The global healthcare products maker raised its full-year guidance in the Q3 2026 earnings report released on…
Johnson & Johnson reports results from Phase 3 FUZION study
Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA, or guselkumab, maintained or improved fistula remission through 48 weeks in adults with Crohn’s disease, or…
Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings...
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $JNJ--JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law.
Johnson & Johnson price target raised to $287 from $275 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Johnson & Johnson (JNJ) to $287 from $275 and keeps an Overweight rating on the shares. With 100% deal…